Prediction of the pharmacokinetic parameters of reduced- dolasetron in man using in vitro-in vivo and interspecies allometric scaling

References

• ASHFORTH, E. I. L., CARLILE, D. J., C HENERY, R. and HOUSTON, J. B., 1995, Prediction of in vivo disposition from in vitro system : clearance of phenytoin and tolbutamide using rat hepatic microsomal and hepatocyte data. Journal of Pharmacology and Experimental Therapeutics, 274, 761–766.
   Google Scholar
• AUDHUY, B., CAPPELAERE, P., MARTIN, M., CERVANTES, A., FABBRO, M., RIVIERE, A., K HAYAT D., B LEIBERG, H., FARALDI M. and C LAVERIE, N., 1996, A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. European Journal of Cancer, 32A, 807–813.
   Google Scholar
• BAARNHIELM, C., D AHLBACK, H. and S KANBERG, I., 1986, In vitro pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharmacologica et Toxicologicd 59, 113–122.
   PubMedGoogle Scholar
• BOEIJINGA, P. H., G ALVAN, M ., BARON, B. M., D UDLEY M W S IEGEL, B. W. and S TONE, A. L., 1992, Characterization of the novel 5-HT 3 receptor antagonist MDL 73,147EF (Dolasetron mesilate) and MDL 74,156 in NG 108–15 neuroblastoma X glioma cells. European Journal of Pharmacology, 219, 9–13.
   Google Scholar
• BOXENBAUM, H. 1982, Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics, 10, 201–227.
   PubMedGoogle Scholar
• BOXENBAUM, H., 1984, Interspecies pharmacokinetic scaling and the evolutionary-comparative para-digm. Drug Metabolism Reviews, 15, 1071–1121.
   PubMed Web of Science ®Google Scholar
• BOXENBAUM, H. and D'S OUZA, R. W., 1990, Interspecies pharmacokinetic scaling, biological design and neotensy. In Advances in Drug Research, edited by B. Testa (London: Academic), pp. 139–196.
   Google Scholar
• BOXENBAUM, H. and DI LEA, C., 1995, First- time- in-human dose selection: allometric thoughts and perspectives. Journal of Clinical Pharmacology, 35, 957–966.
   PubMed Web of Science ®Google Scholar
• BOXENBAUM, H. and FERTIG, J. B., 1984, Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. European Journal of Drug Metabolism and Pharmacokinetics, 9, 177–183.
   PubMed Web of Science ®Google Scholar
• BOXENBAUM, H., G ILLESP1E, T., HECK, K. and H AHNE, W., 1992, Human dolasetron pharmacokinetics: I. Disposition following single dose intravenous administration to normal male subjects. Biopharmaceutics and Drug Disposition, 13, 693–701.
   Google Scholar
• BOXENBAUM, H., G ILLESP1E, T., HECK, K. and H AHNE, W., 1993, Human dolasetron pharmacokinetics: II. Absorption and disposition following single dose oral administration to normal male subjects. Biopharmaceutics and Drug Disposition, 14, 131–141.
   Google Scholar
• CHIBA, M., FUJITA, S. and Suzum, T., 1990, Pharmacokinetic correlation between in vitro hepatic microsomal enzyme kinetics and in vivo metabolism of imipramine and desipramine in rats. Journal of Pharmaceutical Sciences, 79, 281–287.
   PubMed Web of Science ®Google Scholar
• CRUZE, C. A., KM, G. R. and MEREDITH, M. P., 1995, Interspecies scaling of tebufelone pharmaco-kinetic data and application to preclinical toxicology. Pharmaceutical Research, 12, 895–901.
   PubMedGoogle Scholar
• DAVIES, B. and MORRIS, T., 1993, Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 10, 1093–1095.
   PubMed Web of Science ®Google Scholar
• DEDRICK, R. L., B ISCHOFF, K. B. and ZAHARKO, D. S., 1970, Interspecies correlation of plasma concentration, history of methotrexate (NSC- 740). Cancer Chemotherapy Report, 54, 95–101.
   PubMedGoogle Scholar
• DOW, J. and BERG, C., 1995, Stereoselectivi ty of the carbonyl reduction of dolasetron in rats, dogs and humans. Chirality,, 7, 342–348.
   PubMed Web of Science ®Google Scholar
• DOW, J., DI FRANCESCO, G. F. and BERG, C., 1996, Comparison of the pharmacokinetics of dolasetron and its major active metabolite reduced dolasetron in dog. Journal of Pharmaceutical Sciences, 85, 685–689.
   Google Scholar
• GALVAN, M GITTOS M W., MILLER, R. C., MOSER, P. C., VAN G IERSBERGEN, P. L. M. and FOZARD, J. R., 1992, Dolasetron mesilate (MDL 73,147EF), a potent anti-emetic 5-HT 3 receptor antagonist. British Journal of Pharmacology, 107, 449P.
   Google Scholar
• HAYES, K. A., B RENNAN, B., CHENERY, R. and HOUSTON, J. B., 1995, In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metabolism and Disposition, 23, 349–353.
   PubMed Web of Science ®Google Scholar
• HOENER, B., 1994, Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharmaceutics and Drug Disposition, 15, 295–304.
   PubMed Web of Science ®Google Scholar
• HOUSTON, J. B., 1994, Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochemical Pharmacology, 47, 1469–1479.
   PubMed Web of Science ®Google Scholar
• HUEBERT, N. D., SCHWARTZ, J.-J., H INZE, C. and H AEGELE K. D., 1994, Bioavailability and the effect of food on the pharmacokinetics of dolasetron mesilate and its active metabolite, MDL74156, in man. British Journal of Clinical Pharmacology, 37, 120P–121P.
   Google Scholar
• HUEBERT, N. D., S CHWARTZ, J.-J., ZEIDLER, L., S CHWACH, V. and H AEGELE, K. D., 1996, Simultaneous measurement of dolasetron and its major metabolite, MDL74156, in human plasma and urine. Journal of Chromatography B: Biomedical Applications (in press).
   Google Scholar
• HUSSEY, E. K., Doc, K. H., D ANIEL, M. J., HALL, S. T., HARKER, A. J. and EVANS, G. L., 1994, Interspecies scaling and pharmacokinetic parameters of 3TC in humans. Journal of Clinical Pharmacology, 34, 975–977.
   Google Scholar
• INGS, R. M. J., 1990, Interspecies scaling and comparisons in drug development and toxicokinetics. Xenobiotica, 20, 1201–1231.
   PubMed Web of Science ®Google Scholar
• KRIS, M G., GRUNBERG, S. M GRALLA, R. J., BALTZER, L., ZARETSKY, S., LIFSEY, D., TYSON, L. B., S CHMIDT, L. and H AHNE W. F., 1994, Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. Journal of Clinical Oncology, 12, 1045–1049.
   Google Scholar
• LAVE, T., SCHMITT - HOFFMANN, A. H., C OASSOLO, P., VALLES, B., UBEAUD, G., BA, B., BRANDT, R. and CHOU, R. C., 1995, A new extrapolation method from animal to man: application to a metabolized compound, mofarotene. Life Sciences, 56, 473–478.
   Google Scholar
• LAVE, T., COASSOLO, P., UBEAUD, G., BRANDT, R., S CHMITT, C., DUNN, S., JAECK, D. and C HOU, R. C., 1996a, Interspecies scaling of Bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling. Pharmaceutical Research 13, 97–101.
   PubMed Web of Science ®Google Scholar
• LAVE, T., D UPIN, S., S CHMITT, M. et al., 1996b, Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransfera se (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans. Xenobiotica, 26, 839–851.
   Google Scholar
• MAHMOOD, I. and B ALIAN, J. D., 1996, Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. Journal of Pharmaceutical Sciences, 85, 411–414.
   PubMed Web of Science ®Google Scholar
• MORDENTI, J., 1986, Man versus beast: pharmacokinetic scaling in mammals. Journal of Pharmaceutical Sciences, 75, 1028–1040.
   PubMed Web of Science ®Google Scholar
• RANE, WILKINSON, G. R. and S HAND, D. G., 1977, Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. Journal of Pharmacology and Experimental Therapeutics, 200, 420–424.
   Google Scholar
• REITH, M. K., S PROLES, G. D. and C HENG, L. K., 1995, Human metabolism of dolasetron mesylate, a5-HT 3 receptor antagonist. Drug Metabolism and Disposition, 23, 806–812.
   PubMed Web of Science ®Google Scholar
• SANWALD P., DAVID, M. and Dow, J., 1996a, Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron: comparison with other indole containing 5-HT 3 antagonists. Drug Metabolism and Disposition, 24, 602–609.
   Google Scholar
• SANWALD P., DAVID, M. and Dow, J., 1996b, The use of electrospray ionization-liquid chromatography-mass spectrometry to study the role of CYP2D6 in the in vitro metabolism of 5- hydroxytryptami ne receptor antagonists. Journal of Chromatography B. Biomedical Applications, 678, 53–61.
   Google Scholar
• SANWALD P., H UEBERT, N. D. and H AEGELE K. D., 1994, Simultaneous measurement of the major metabolites of dolasetron mesilate in human urine using solid-phase extraction and high-performance liquid chromatography. Journal of Chromatography B.• Biomedical Applications, 661, 101–107.
   Google Scholar
• SAWADA, Y., HANANO, M., SUGIYAMA, Y. and I GA, T., 1984, Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharmaceutics, 12, 241–261.
   PubMedGoogle Scholar
• UBEAUD, G., SCHMITT, C., JAECK, D., LAVE, T. and C OASSOLO, P., 1995, Bosentran, a new endothe lin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vitro and in vivo data. Xenobiotica, 25, 1381–1390.
   PubMed Web of Science ®Google Scholar
• WILKINSON, G. R., and SHAND, D. G., 1975, A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics, 18, 377–390.
   PubMed Web of Science ®Google Scholar
• ZOMORODI, K., CARLILE, D. J. and HOUSTON, J. B., 1995, Kinetics of diazepam metabolism in rat hepatic microsomes and hepatocytes and their use in predicting in vivo hepatic clearance. Xenobiotica, 25, 907–916.
   PubMed Web of Science ®Google Scholar